The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of Ori-C101, an armored GPC3-directed CAR-T, in patients with advanced hepatocellular carcinoma (HCC).
 
Jia Fan
No Relationships to Disclose
 
Jian Zhou
Consulting or Advisory Role - AstraZeneca; MSD
Research Funding - Akeso-Sino Pharma Co., Ltd. (Inst); AstraZeneca (Inst); BeiGene (Inst); Chia Tai Tianqing Pharmaceutical Group (Inst); Eddingpharm (Suzhou) Co., Ltd. (Inst); Eisai China Inc. (Inst); Fosun Pharma (Inst); Gilead Sciences (Inst); Innovent Biologics (Inst); Jiangsu Hengrui Medicine (Inst); Junshi Biosciences (Inst); MSD (Inst); OriCell Therapeutics Co.,Ltd. (Inst); Qilu Pharmaceutical (Inst); Roche (Inst); Singlera genomics (Inst); Suzhou Zelgen Biopharmaceuticals Co., Ltd. (Inst)
 
Xiao-Wu Huang
No Relationships to Disclose
 
Qiang Gao
No Relationships to Disclose
 
Jieyi Shi
No Relationships to Disclose
 
Yi-Feng He
No Relationships to Disclose
 
Zaozhuo Shen
No Relationships to Disclose
 
Wenwen Wang
No Relationships to Disclose
 
Sidi Wei
No Relationships to Disclose
 
Lan Gu
No Relationships to Disclose
 
Li Zheng
No Relationships to Disclose
 
Shanzhi Gu
No Relationships to Disclose
 
Zhongwei Zhao
No Relationships to Disclose
 
Rick Xu
No Relationships to Disclose
 
Qian Zhang
No Relationships to Disclose
 
Bin Li
No Relationships to Disclose
 
Yu Tang
No Relationships to Disclose
 
Xiaomin Ding
No Relationships to Disclose
 
Xiaowen He
No Relationships to Disclose